Quantitative analysis showed a nearly two-fold increase in the percentage of β-III Tubulin+NeuN+-labeled neurons among the WT+PBS and hDPSCs-treated mice compared to AD+PBS mice, with no statistically significant difference (Figure 8C, D). This evidence concerns the gene RBFOX3 and Alzheimer disease.